Background
==========

Lung cancer, the main cause of cancer-related deaths, is the most common malignancy all over the world \[[@b1-medscimonit-24-9504]\]. NSCLC is a common disease and accounts for about 80% of all lung cancers \[[@b2-medscimonit-24-9504],[@b3-medscimonit-24-9504]\]. Currently, the main treatments for NSCLC patients are surgical resection, radiation therapy, and chemotherapy \[[@b4-medscimonit-24-9504],[@b5-medscimonit-24-9504]\]. Although remarkable improvements have been made in those treatments, the curative effects are still unsatisfactory and over 160 000 patients die per year worldwide \[[@b6-medscimonit-24-9504],[@b7-medscimonit-24-9504]\]. Because most NSCLC patients are diagnosed at late stage, the prognosis of NSCLC patients is poor and the 5-year survival rate for NSCLC patients is less than 15% \[[@b8-medscimonit-24-9504]--[@b10-medscimonit-24-9504]\]. Therefore, novel and available bio-markers for the diagnosis of NSCLC patients are urgently need.

Fork-head box D3 (*FOXD3*) is a protein-coding gene that locates at chromosome 1p 31.3 and a winged-helix transcription factor that belongs to the fork-head box (FOX) transcription factor family \[[@b11-medscimonit-24-9504]--[@b13-medscimonit-24-9504]\]. It was initially identified because of its expression in embryonic stem cells, and it plays multiple important roles in vertebrate embryogenesis, including control of dorsal mesoderm formation, maintenance of self-renewal and multi-potency of stem cells, and regulation of neural crest development \[[@b14-medscimonit-24-9504]--[@b18-medscimonit-24-9504]\]. Ectopic expression of *FOXD3* has been proved to suppress the invasion, migration, and spheroid outgrowth of mutant B-RAF melanoma cells \[[@b19-medscimonit-24-9504]\]. In addition, dysregulation of *FOXD3* has been observed in gastric cancer, breast cancer, and neuroblastoma \[[@b20-medscimonit-24-9504]--[@b22-medscimonit-24-9504]\]. However, its diagnostic value in NSCLC has rarely been reported.

In the present study, we investigated the expression of *FOXD3* and analyzed the correlation of *FOXD3* expression and clinical features. We also assessed the diagnostic role of *FOXD3* in NSCLC.

Material and Methods
====================

Patients
--------

The present study was performed in the Fourth Affiliated Hospital of China Medical University and was approved by the Ethics Committee of the Fourth Affiliated Hospital of China Medical University during April 2011 and June 2015. A total of 131 patients who were diagnosed with NSCLC were enrolled in the present study. None of the patients had received any preoperative treatment, including radiotherapy and chemotherapy, before sampling. In addition, 63 healthy volunteers were enrolled as healthy controls. Written informed consent was provided by each participant in advance.

We obtained 10 ml peripheral blood from each participant and stored the samples at room temperature. After centrifugation at 3000 rpm at 4°C, the obtained serum was put into EDTA blood collection tubes and stored at −80°C until use. Clinicopathologic characteristics of each patient were recorded in a database.

RNA extraction and qRT-PCR analysis
-----------------------------------

Total RNA was extracted from serum samples using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). Then, the first chain of cDNA was synthesized via reverse transcription using the Primer Script RT Master Kit (TAKARA, China). RT-PCR reaction was performed using the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, USA). U6 small nuclear (U6) was used as internal control. The relative mRNA expression of *FOXD3* was calculated using the 2^−ΔΔt^ method. Each sample was assessed in triplicate.

Western blotting
----------------

Total protein was isolated from all samples. The protein concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) and separated by 10% sodium dodecyl sulfate-polyacrylamide gel for electrophoresis (SDS-PAGE). The brands were transferred onto nitrocellulose filter membranes. After the membranes were blocked with 5% non-fat milk, they were incubated with primary antibodies against FOXD3 or GPADH (Abcam, Cambridge, MA, USA), followed by incubation with horseradish peroxidase-conjugated IgGs. Target protein was detected by an enhanced chemiluminescence substrate kit (Pierce Biotechnology, Rockford, IL, USA).

Statistical analysis
--------------------

The data were analyzed using SPSS 18.0 software and the figures were designed with GraphPad Prism 5. The differences between 2 groups were analyzed by *t* test. The chi-square test was used to analyze the relationship of *FOXD3* expression with clinical parameters of NSCLC patients. The ROC curve was plotted to evaluate the diagnostic value of *FOXD3* in patients with NSCLC compared to healthy controls. The difference was considered to be statistically significant when *P* was less than 0.05.

Results
=======

Down-regulation of serum *FOXD3* at mRNA level was observed in NSCLC patients
-----------------------------------------------------------------------------

The relative mRNA expression of serum *FOXD3* in NSCLC patients and healthy controls was determined by qRT-PCR analysis. As shown in [Figure 1](#f1-medscimonit-24-9504){ref-type="fig"}, the serum *FOXD3* expression in NSCLC patients was lower than that in healthy controls (2.01±0.44 versus 2.62±0.46, *P*\<0.001).

The protein expression of *FOXD3* in NSCLC patients
---------------------------------------------------

Western blotting was used to measure the protein expression of *FOXD3* in NSCLC patients and healthy controls. The result demonstrated that serum FOXD3 protein was decreased in NSCLC patients compared to healthy controls (0.69±0.39 *vs.* 1.04±0.59, [Figure 2](#f2-medscimonit-24-9504){ref-type="fig"}, *P*\<0.001).

Association of *FOXD3* expression and clinical parameters of NSCLC patients
---------------------------------------------------------------------------

To analyze the relationship of *FOXD3* and clinical features of NSCLC patients, the chi-square test was used. The outcome revealed that the low expression of *FOXD3* was positively associated with TNM stage (*P*=0.014), lymph node metastasis (*P*=0.021), and differentiation (*P*=0.035). However, there was no significant difference between *FOXD3* expression and age, histology, or smoking ([Table 1](#t1-medscimonit-24-9504){ref-type="table"}, *P*\>0.05).

The diagnostic value of *FOXD3* in NSCLC
----------------------------------------

The ROC curve was plotted to assess the diagnostic potential of *FOXD3* in patients with NSCLC. The outcome demonstrated that *FOXD3* expression was able to efficiently distinguish NSCLC patients from controls (AUC=0.826, 95%CI=0.766-0.885, *P*\<0.0001). According to the ROC curve ([Figure 3](#f3-medscimonit-24-9504){ref-type="fig"}), the optimal cutoff point of *FOXD3* expression was 2.38. Based on the cutoff point, a sensitivity of 77.1% and a specificity of 74.6% were obtained.

Discussion
==========

NSCLC is a common, slow-developing lung cancer with complex pathogenesis; its progression involves in not only several stages, but also many oncogenes and tumor suppressor genes \[[@b23-medscimonit-24-9504],[@b24-medscimonit-24-9504]\]. Bai et al. found that *miR-32* was associated with progression and predicted the prognosis of NSCLC \[[@b25-medscimonit-24-9504]\]. Jiang et al. \[[@b26-medscimonit-24-9504]\] reported that *HE4* serves as a tumor marker for NSCLC, and its low expression can predict a poor prognosis of NSCLC patients. Ke et al. revealed that the over-expression of *CTHRC1* was related to tumor aggressiveness and prognosis of human NSCLC \[[@b27-medscimonit-24-9504]\]. It was demonstrated by Ji et al. that low expression of *PTRN* and over-expression of *Ki67* were correlated with lymph node metastasis and malignant invasion of NSCLC \[[@b23-medscimonit-24-9504]\].

*FOXD3* is a member of the winged-helix/fork-head transcription factor family, which is characterized by a conserved domain containing 100 residues and that is required for the activity of DNA-binding \[[@b18-medscimonit-24-9504]\]. It is mainly expressed in the multi-potent cells, including embryonic stem cells and tumor cells. Reports have revealed that *FOXD3* plays important roles in the maintenance and self-renewal of embryonic stem cells, and is strongly related to the early development of embryos \[[@b23-medscimonit-24-9504]\]. Studies on the effects of *FOXD3* on tumor stem cells have also been reported. Steiner et al. suggested that *FOXD3* was essential for the development of xenopus dorsal mesoderm \[[@b28-medscimonit-24-9504]\]. It was reported by Teng et al. that *FOXD3* was required in maintaining the progenitors of the neural crest \[[@b29-medscimonit-24-9504]\]. All these reports provide theories relevant to studying the relationship between *FOXD3* and NSCLC.

In addition, Ectopic expression of *FOXD3* has been reported in various diseases. Wang et al. reported that *FOXD3* was down-regulated in lung cancer and could suppress the development of this disease \[[@b11-medscimonit-24-9504]\]. Low expression of *FOXD3* in breast cancer was reported by Zhao et al. \[[@b21-medscimonit-24-9504]\]. In the present study, we first detected the expression of *FOXD3* in NSCLC patients, showing that the expression level of *FOXD3* was significantly lower in NSCLC patients than in controls at mRNA and protein levels, which was in accord with previous studies. It can be concluded that *FOXD3* might be a tumor suppressor in NSCLC.

Then, we assessed the correlation of *FOXD3* with the tumorigenesis of NSCLC by analyzing the relationship of *FOXD3* expression and clinical features of NSCLC patients.*FOXD3* was proved to have close relationships with differentiation, TNM stage, and lymph node metastasis. Subsequently, in order to explore the diagnostic value of *FOXD3* in patients with NSCLC, an ROC curve was built. As a result, a high AUC, as well as high sensitivity and specificity, were obtained, showing that *FOXD3* is an independent diagnostic marker in NSCLC.

In previous studies, the precise mechanism and function of*FOXD3* in the tumorigenesis and progression of diseases were revealed and it was reported that it cannot be regulated by some genes. For instance, Basile et al. showed that *FOXD3* affects mutant B-RAF melanoma cells via regulating *PLX4032/*4720 \[[@b30-medscimonit-24-9504]\]. Guo et al. found that *FOXD3* interacted with*Oct-4* to regulate the expression of endodermal specific promoter \[[@b31-medscimonit-24-9504]\]. Liu et al. demonstrated that *FOXD3* regulates the expression of microRNA-137 tumor growth in hepatocellular cancer \[[@b32-medscimonit-24-9504]\]. However, its mechanisms in NSCLC remains unclear. Our group plans to explore this topic further in future research

Conclusions
===========

*FOXD3* is down-regulated and plays an important role in the development of NSCLC. In addition, it can act as a diagnostic bio-marker for patients with NSCLC. The present study is limited by its small samples size and further studies are needed.

**Source of support:** Departmental sources
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###### 

Relationship between *FOXD3* expression and clinical parameters of patients with NSCLC.

  Clinical parameters        Case (n=131)   *FOXD3* expression   χ^2^   *P* value   
  -------------------------- -------------- -------------------- ------ ----------- -------
  Age                                                                   0.090       0.764
   ≤55                       61             43                   18                 
   \>55                      70             51                   19                 
  Histology                                                             1.863       0.172
   Squamous cell carcinoma   69             46                   23                 
   Adenocarcinoma            62             48                   14                 
  Smoking                                                               0.332       0.564
   Yes                       76             56                   20                 
   No                        55             38                   17                 
  TNM stage                                                             6.092       0.014
   I, II                     66             41                   25                 
   III, IV                   65             53                   12                 
  Lymph node metastasis                                                 5.336       0.021
   Yes                       74             59                   15                 
   No                        57             35                   22                 
  Differentiation                                                       4.421       0.035
   High/moderate             58             47                   11                 
   Low                       73             47                   26                 
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